2012-10-05 16:30:52 - Recently published research from Global Markets Direct, "Cirrhosis - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Cirrhosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cirrhosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cirrhosis. Cirrhosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Full Report Details at

- www.fastmr.com/prod/468361_cirrhosis_pipeline_review_h2_2012.asp ..


Scope

* A snapshot of the global therapeutic scenario for Cirrhosis.
* A review of the Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Cirrhosis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Cirrhosis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Cirrhosis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cirrhosis Overview
Therapeutics Development
An Overview of Pipeline Products for Cirrhosis
Cirrhosis Therapeutics under Development by Companies
Cirrhosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Cirrhosis Therapeutics - Products under Development by Companies
Cirrhosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Cirrhosis Therapeutics Development
AlbireoPharma
Shenzhen Beike Biotechnology Co., Ltd.
Ocera Therapeutics, Inc.
NovImmune SA
Intercept Pharmaceuticals, Inc.
PharmaEssentia Corporation
Stelic Institute & Co.
Dr. Falk Pharma GmbH
Centocor Ortho Biotech, Inc.
PharmaIN Corporation
Stempeutics Research Private Limited
Cirrhosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
NI-0801 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ustekinumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEGylated-Interferon-beta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STNM-04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sorafenib tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous CD133 + Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
temsirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terlipressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Budesonide + Ursodeoxycholic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
terlipressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
peginterferon alfa-2a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lenograstim + Haematopoietic Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
zinc acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fenofibrate + Ursodeoxycholic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bone Marrow Derived CD133+ Stem Cells Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468361&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.